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Abstract
Objectives: A marked decline in suicide rates has co-occurred with increased antidepressant sales in several countries but
the causal connection between the trends remains debated. Most previous studies have focused on overall suicide rates
and neglected differential effects in population subgroups. Our objective was to investigate whether increasing sales of
non-tricyclic antidepressants have reduced alcohol- and non-alcohol-related suicide risk in different population subgroups.
Methods: We followed a nationally representative sample of 950,158 Finnish adults in 1995–2007 for alcohol-related
(n = 2,859) and non-alcohol-related (n = 8,632) suicides. We assessed suicide risk by gender and social group according to
regional sales of non-tricyclic antidepressants, measured by sold doses per capita, prevalence of antidepressant users, and
proportion of antidepressant users with doses reflecting minimally adequate treatment. Fixed-effects Poisson regression
models controlled for regional differences and time trends that may influence suicide risk irrespective of antidepressant
sales.
Results: The number of sold antidepressant doses per capita and the prevalence of antidepressant users were unrelated to
male suicide risk. However, one percentage point increase in the proportion of antidepressant users receiving minimally
adequate treatment reduced non-alcohol-related male suicide risk by one percent (relative risk 0.987, 95% confidence
interval 0.976–0.998). This beneficial effect only emerged among men with high education, high income, and employment,
among men without a partner, and men not owning their home. Alcohol-related suicides and female suicides were
unrelated to all measures of antidepressant sales.
Conclusion: We found little evidence that increase in overall sales or in the prevalence of non-tricyclic antidepressant users
would have caused the fall in suicide rates in Finland in 1995–2007. However, the rise in the proportion of antidepressant
users receiving minimally adequate treatment, possibly due to enhanced treatment compliance, may have prevented non-
alcohol-related suicides among men.
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Introduction
Suicide rates have declined markedly in recent decades in
several countries [1]. This decline has, in many countries, co-
occurred with an emergence and expansion in the use of new-
generation antidepressants, namely selective serotonin reuptake
inhibitors (SSRIs) and other non-tricyclic antidepressants [2,3].
Since depression and other psychiatric disorders treated with
antidepressants are major risk factors for suicide [4] it is plausible
that more extensive mental health treatment has contributed to
the decline in suicide rates. However, the causal connection
remains debated [5,6].
Suicide is a rare event and even large meta-analyses of
randomized controlled trials have lacked statistical power to
observe a significant effect of SSRIs on suicide risk, but have
observed an increase in non-fatal suicide attempts during SSRI
treatment [7,8]. However, short follow-up times (8–10 weeks) of
trials hinder the assessment of possible long time benefits of
antidepressants [7]. A meta-analysis of large observational studies
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using individual-level data, with sufficient statistical power and
longer follow-ups (2 months–7 years) reported a 40% decrease in
odds of suicide among depressed adults and elderly using SSRIs
[9]. A challenge with individual-level observational studies is the
possibility of confounding by indication i.e. antidepressant use is
not randomly allocated but is influenced by factors such as
depression severity, suicidal ideation, and suicidal behavior, which
are difficult to fully control for [9].
To overcome problems of confounding by indication many
studies have used aggregate-level designs. Most aggregate-level
studies have reported descriptive national trends or crude
temporal correlations [1], although an increasing number of
national [2,10–15] and cross-national [16,17] studies have used
more sophisticated statistical methods, assessing regional level
variation in antidepressant use and suicides, stratifying by age and
gender, and controlling for regional changes in unemployment,
divorce rates, and alcohol consumption. Aggregate-level studies
have mostly found a significant beneficial effect of antidepressants
on suicide rate in at least some age groups [1,11–14,16,17].
However, they have rarely controlled for time trends and thus part
of the observed association may be due to mere co-occurrence of
two causally unrelated developments. It can be argued that time-
controls are an over-adjustment [17] as they control for everything
that is common across regions–including similar antidepressant
sale trends. However, controlling for time is still the most stringent
test for causality because it removes the confounding effects of all
other co-occurring trends in observed and unobserved factors such
as the national economy, alcohol consumption, and divorce rates
that are common across regions, thus inferring effects only from
the variation between regions in the changes in antidepressant
sales. Studies controlling for time have yielded mixed results. A
Norwegian study [2] only found an effect during times of low
antidepressant sales, whereas a Swedish [10] and a Finnish study
[15] found no effects in models where time was controlled for. The
Finnish study [15] did report a significant effect from a model with
multiple interactions between antidepressant use, region, time,
age, and gender, but not for simpler models. Moreover the
significant effect may need to be interpreted with caution as it
would imply a much faster decline in suicide rates than has been
observed in Finland.
One of the methodologically most convincing studies, with
appropriate time-controls, exploited between-country variation in
how new medication is adopted and diffused to predict the fall in
suicide rates in 26 countries [16]. In countries where diffusion of
new medication was early and quick, SSRIs tended to diffuse
quickly as well, and this was associated with a more rapid fall in
suicide rates, suggesting a 5% decrease in suicide rates per 1 pill
per-capita-per-year increase in SSRI sales. A caveat with this study
was that it studied total populations without differentiation of
antidepressant exposure according to important population
subgroups such as gender or socioeconomic group. Since
antidepressant use is more common among women, whereas
suicides are more common among men, combining genders in
analyses is not without problems–an increased use of antidepres-
sants among women may have little effect on suicides among men.
The same applies for socioeconomic groups: in Finland suicide is
more common among those with low social position [18,19] while
social group differences in antidepressant use are smaller or even
reversed [20]. Antidepressants are likely to prevent suicide only in
groups who are adequately treated. To the best of our knowledge,
no previous study has assessed the association of antidepressants
and suicide rate by social group.
Previous studies have also largely neglected different types of
suicides. Alcohol-related suicides, i.e. suicides where alcohol
intoxication is a contributory cause, are common among men
and among individuals with low socioeconomic position [18,19].
Alcohol-related suicides are also particularly common in depres-
sion, accounting for 35% of the excess suicides among depressed
men and 10–20% among women [21]. It is unclear whether the
expansion of antidepressant treatment has had beneficial effects on
alcohol-related suicides.
Current study
We use large Finnish register-based data to estimate the
association between regional antidepressant sales and suicide risk.
Our rationale is that where and when antidepressant sales are
high, depressed individuals are more likely to be treated than
where and when sales are low. If antidepressants reduce suicide
risk, then the higher likelihood of being treated should be reflected
in the lower likelihood of suicide. This assumption only holds if
there are no regional and temporal differentials in factors leading
to suicide, such as depression or alcohol consumption, and these
evident differentials need to be controlled for. To do this we use a
fixed-effects model that controls for all time invariant character-
istics of regions as well as all national-level year-specific
characteristics that may influence suicide risk irrespective of
regional antidepressant sales. We add to the current literature in
three ways. We (1) study non-alcohol-related and alcohol-related
suicides separately; (2) assess the effects of antidepressant sales
according to gender, socioeconomic position, employment status,
and living arrangements in order to establish whether increased
antidepressants sales have had similar effects across population
subgroups; (3) use various measures for regional antidepressant
sales–sold doses per capita, prevalence of antidepressant users, and
the proportion of antidepressant users with doses reflecting
minimally adequate treatment–in order to assess which dimensions
of increased sales could explain the fall in suicide rates.
Methods and Materials
Ethics Statement
The study has been approved by Statistics Finland Board of
Statistical Ethics (permit TK-53-1519-09). Informed consent from
participants was not obtained, since the data were collected for
routine administrative registration purposes and were anonymized
prior to analysis.
Data
Our data were based on individual-level registers on population,
mortality, and health care covering all permanent residents of
Finland. We obtained an 11% random sample of individuals aged
20 years or older at the end of any year 1994–2007, plus an 80%
oversampling of individuals who died during this period
(altogether 950,158 persons, 8,353,112 person-years, and 11,491
suicides). All analyses were weighted according to the differential
sampling probabilities. The sample was drawn from population
registers at Statistics Finland and included annual sociodemo-
graphic information and cause-specific mortality follow-up until
the end of 2007. The sample was linked with individual-level
information on all purchases of antidepressants in 1995–2007 from
the registers of the Social Insurance Institution. Statistics Finland
used personal identification numbers to combine data from
different registers.
Variables
Suicide. Suicides were classified according to the Interna-
tional Classification of Diseases (ICD) 9 and 10 (1995: ICD-9
codes E950–E959; 1996–2007: ICD-10 codes X60–X84, Y870).
Antidepressant Sales and Suicide in Finland
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Suicides were divided into alcohol-related and non-alcohol-related
according to whether the death certificate stated alcohol intoxi-
cation as one of the three contributory causes of death. We
observed 2,859 alcohol-related and 8,632 non-alcohol-related
suicides.
Antidepressant sales. Data on antidepressant sales came
from the register of the Social Insurance Institution, which covers
individual-level information on all prescription medication pur-
chases gathered from all Finnish retail pharmacies, but excludes
medication administered at hospitals and other institutional
settings. In 1995–2007 the proportion of antidepressants sold by
retail pharmacies increased from 89% to 96% [22,23]. We used
yearly information on purchases of non-tricyclic antidepressants
(N06AB, N06AG, N06X, and N06AA22 in the Anatomical
Therapeutic Chemical Classification System). Tricyclic antide-
pressants (other N06AA, currently around 7% of all sold
antidepressant doses [24]) were excluded because little change in
their sales has occurred in Finland in recent decades [24], and they
are thus unlikely to have had major impact on declining suicide
rates. Including tricyclic antidepressants in sensitivity analyses did
not change the results.
Individual-level antidepressant use is not a suitable exposure in
this setting because antidepressant users may be more likely to
commit suicide due to their underlying mental health problems.
We thus used regional sales of non-tricyclic antidepressants to
indicate the antidepressant treatment possibilities individuals
would have if they were depressed. We aggregated these from
individual-level information on antidepressant purchases by
region, year, and gender for the period 1995–2007. We used
three measures for regional antidepressant sales:
1) The number of purchased defined daily doses (DDD) of non-
tricyclic antidepressants per capita per year captures the
amount of antidepressants sold overall. DDD is the assumed
average daily dose of a given drug for its main indication, set
by the World Health Organization, and is one of the most
commonly used measure in previous aggregate-level studies
on the antidepressant-suicide association [1].
2) The yearly regional prevalence of people with at least one
antidepressant purchase reflects the proportion of the
population who were actually using antidepressants. Among
individuals with at least one purchase 76% had two or more
purchases.
3) The proportion of individuals with a yearly minimum of 90
DDDs of antidepressant purchases among all individuals with
at least one antidepressant purchase. This corresponds to a
prescription of three months or more–the general length of
the acute phase treatment of depression [25] –and is used as a
proxy for the proportion of antidepressant users who received
doses reflecting minimally adequate treatment. We also
performed sensitivity analyses where we defined minimally
adequate treatment as having a minimum of 180 DDDs of
antidepressant purchases. This would correspond to acute and
continuation phase of treatment.
Region of residence was updated annually and was measured by
the so-called NUTS3 regions (n = 21) stipulated by the European
Union, which roughly correspond to the Finnish hospital districts,
with the exception of the Helsinki metropolitan area (cities of
Helsinki, Vantaa, Espoo, and Kauniainen) separated from the
surrounding region. In our sample the number of individuals per
region varied from 5,210 to 182,199.
Social factors. In order to assess whether the rise in
antidepressant sales has affected suicide risk similarly across social
groups, we used annual individual-level measures of socioeco-
nomic position, employment status, and living arrangements
obtained from end-of-year registers of Statistics Finland. Educa-
tion was based on highest achieved qualification and classified as
more than nine years and nine years or less. Employment status
was measured at the end of each year and included employed
persons and others. Individual income tertiles were calculated
from the combined population of men and women. The 2nd and
3rd tertiles were combined and compared with the lowest tertile.
Homeowners were compared to those living in rented or other
housing, and those living with a partner were compared to those
without a partner. Antidepressant sales were not disaggregated by
social factors.
Statistical analyses
We used individual-level Poisson-models to examine how
fluctuations in regional antidepressant sales were associated with
changes in suicide risk in 1995–2007. We applied a region and
time fixed-effects approach to control for all regional and temporal
variation that may affect suicide risk irrespective of antidepressant
sales [26]. We estimated three models. The age-adjusted Model 1
was a reference model that incorporated all variation between
regions and years. This model is potentially biased by regional
differences in mental health, since both suicide rates and
antidepressant sales are likely to be high in regions with a high
prevalence of depression, and the potential beneficial effect of
antidepressants will be suppressed. In order to control for any
time-invariant regional characteristics we added regional fixed
effects in Model 2. In Model 3, we introduced national-level year
fixed effects (as single-year dummy variables) to control for all
variation in suicide risk common to all regions in a given year
irrespective of their antidepressant sales.
Each year 1995–2007, all individuals present and aged 20+ at
the last day of the previous year were followed up for death or end
of year. The Poisson-model for binary data allowed us to assess
suicide risk in relation to person-time rather than number of
persons at risk [27], however, sensitivity analyses with logistic
models yielded similar results. As the yearly individual records
were not independent observations we calculated robust standard
errors clustered at the individual level–clustering standard errors at
the regional level yielded similar results. All analyses were
performed separately for men and women adjusting for categorical
age (20–34, 35–49, 50–64, 65–79, and 80+). STATA 11.2 was
used in all analyses [28].
Results
National trends in suicide rates and antidepressant sales
Finland experienced a rapid decline in suicide rates in 1995–
2007 (Figure 1). Most of this decline was accounted for by suicides
where alcohol intoxication was not a contributory cause, whereas
the decline in alcohol-related suicide rates was slower and
stagnated altogether in the beginning of the 2000s. Around 30%
of male suicides and 10–15% of female suicides were alcohol-
related, the proportion slowly increasing among men. In the same
period, non-tricyclic antidepressant sales increased steadily. The
number of sold doses per capita went up from around 5–7 in 1995
to 18 among men and almost 30 among women in 2007. The
2007 sales correspond to an over two week daily use of
antidepressants among men and a one-month daily use among
women per capita per year. The prevalence of having at least one
yearly antidepressant purchase more than doubled during the
study period reaching 6% among men and 10% among women in
2007. The proportion of antidepressant users with doses reflecting
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minimally adequate treatment (i.e. at least 90 defined daily doses
annually) increased from around 60% to 80% among both men
and women.
Regional suicide rates and antidepressant sales
To quantify the temporal connection between falling suicide
rates and antidepressant sales we calculated regional correlations
between age-adjusted suicide rates and antidepressant sales.
Table 1 shows the average of these regional correlations weighted
by population size. The correlations suggest that among men,
regional antidepressant sales could explain at most 40% of the
variation in non-alcohol-related suicide rates and around 10% in
alcohol-related suicide rates. Among women antidepressant sales
could only explain a maximum of 0–10% of the variation in
suicide rates.
Suicide risk by regional antidepressant sales
Table 2 shows the age-adjusted relative risk for suicide per one
unit increase in regional antidepressant sales. Model 1 shows that
one unit increase in the regional number of sold doses per capita
was associated with a 3% decrease in the suicide risk of men and
1% decrease among women. One percentage point increase in the
regional prevalence of antidepressant users was associated with a
9% decrease in male suicides and a 2% decrease in female
suicides. Finally one percentage point increase in the proportion of
antidepressant users receiving doses reflecting minimally adequate
treatment decreased suicide risk by 2% among men and by 1%
among women. These associations were largely similar in alcohol-
and non-alcohol-related suicides.
Model 1 is likely to be biased by regional differences in mental
health and we thus controlled for all time-invariant regional
characteristics by adding regional fixed effects in Model 2. As
expected, the associations between antidepressant sales and suicide
risk strengthened slightly. However in Model 3, when introducing
the year fixed effects that control for all variation in suicide risk
common to all regions irrespective of their antidepressant sales,
only the regional proportion of antidepressant users receiving
minimally adequate treatment was significantly associated with
male risk for non-alcohol-related suicide, with one percentage
point increase in proportion predicting 1% reduction in suicide
risk. Controlling for a linear national time-trend or separate
regional linear time-trends instead of year dummies, as well as
assessing suicide risk with a one-year lag with respect to
antidepressant sales, gave similar, yet non-significant, results (see
Table S1). Including tricyclic medication in the antidepressant
sales did not change the results shown in table 2. However,
defining minimally adequate treatment as a minimum of 180
instead of 90 daily doses per year changed the results somewhat:
the increase in the proportion of antidepressant users having at
least 180 doses had no effect on suicide risk (Table S1).
Variation according to social factors
We also assessed whether the association between antidepres-
sant sales and suicide risk varied by social factors. As the overall
effect was significant only for the proportion of antidepressant
users receiving doses reflecting minimally adequate treatment and
non-alcohol-related suicide among men, we present the social-
group-specific analyses for this association only. Table 3 shows
estimates from age-adjusted models including region and year
fixed effects, stratified by social factors. The p-values for effect
modification by social group come from interaction models
including interactions of the given social factor with antidepressant
sales, age, region, and year. Although according to the p-values,
the effect of antidepressant sales was not significantly modified by
Figure 1. National trends in suicide rates and non-tricyclic
antidepressant sales in Finland. Alcohol-related and non-alcohol-
related suicide rates per 100,000 person-years (panel A), number of
defined daily doses (DDDs) of antidepressants sold per capita per year
(panel B), prevalence of antidepressant users (panel C), and proportion
of individuals among all antidepressant users who have purchased at
least 90 defined daily doses of antidepressants during a year (panel D)
in 1995–2007 among Finnish men (left) and women (right) aged 20+.
doi:10.1371/journal.pone.0098405.g001
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any of the social factors, the significant decrease in suicide risk
according to regional antidepressant sales was observed only in
some groups. Higher regional proportion of antidepressant users
with doses reflecting minimally adequate treatment reduced
suicide risk among men not living in owned housing and not
living with a partner, but not among homeowners and the
partnered. There was also a borderline significant reduction in the
suicide risk of men with more than 9 years of education, with
higher income, and the employed.
We further modelled associations of all measures of antidepres-
sant sales with all measures of suicides for both genders in
population sub-groups but found no other significant effects (data
not shown). Among men a somewhat consistent pattern emerged
with a beneficial effect of higher antidepressant sales among the
employed, those with higher income, homeowners, and the
Table 1. Population-size weighted average of regional correlations between annually measured age-adjusted suicide rates and
sales of non-tricyclic antidepressants in 1995–2007 (N = 273).
All suicides Alcohol-related Non-alcohol-related
Men Women Men Women Men Women
Sold doses per capita 20.62 20.29 20.28 20.05 20.60 20.31
Prevalence of users 20.63 20.28 20.29 20.05 20.60 20.30
% with minimally adequate doses 20.61 20.29 20.32 20.10 20.57 20.29
doi:10.1371/journal.pone.0098405.t001
Table 2. Age-adjusted relative risk (RR) of suicide per unit change in regional non-tricyclic antidepressant sales.
Model 1 Model 2 Model 3
RR 95% CI1 RR 95% CI1 RR 95% CI1
Men (N= 463,807)
All suicides (N = 8,814)
Sold doses per capita 0.972 0.968–0.977 0.971 0.966–0.976 1.005 0.972–1.041
Prevalence of users 0.911 0.896–0.926 0.902 0.886–0.918 1.020 0.904–1.150
% with minimally adequate doses 0.982 0.978–0.985 0.982 0.979–0.985 0.993 0.984–1.003
Non-alcohol-related (N = 6,250)
Sold doses per capita 0.973 0.967–0.978 0.969 0.963–0.975 1.000 0.959–1.042
Prevalence of users 0.913 0.895–0.931 0.895 0.876–0.914 1.034 0.895–1.195
% with minimally adequate doses 0.981 0.977–0.984 0.981 0.977–0.984 0.987 0.976–0.998
Alcohol-related (N = 2,564)
Sold doses per capita 0.972 0.963–0.980 0.977 0.968–0.987 1.019 0.958–1.083
Prevalence of users 0.905 0.877–0.934 0.918 0.888–0.950 0.999 0.805–1.238
% with minimally adequate doses 0.983 0.978–0.989 0.985 0.979–0.991 1.006 0.989–1.023
Women (N= 486,351)
All suicides (N = 2,677)
Sold doses per capita 0.994 0.989–0.999 0.990 0.984–0.995 1.005 0.960–1.053
Prevalence of users 0.982 0.964–1.000 0.966 0.948–0.985 1.025 0.860–1.222
% with minimally adequate doses 0.990 0.984–0.996 0.990 0.984–0.995 1.000 0.976–1.023
Non-alcohol-related (N = 2,382)
Sold doses per capita 0.994 0.989–1.000 0.990 0.984–0.996 0.997 0.949–1.048
Prevalence of users 0.983 0.965–1.002 0.966 0.947–0.986 1.021 0.846–1.231
% with minimally adequate doses 0.991 0.985–0.997 0.990 0.984–0.996 0.997 0.972–1.022
Alcohol-related (N = 295)
Sold doses per capita 0.992 0.975–1.009 0.991 0.974–1.008 1.060 0.935–1.202
Prevalence of users 0.968 0.915–1.025 0.965 0.908–1.025 1.052 0.642–1.725
% with minimally adequate doses 0.985 0.968–1.002 0.986 0.969–1.004 1.025 0.956–1.098
Region fixed effects no yes yes
Year fixed effects no no yes
1CI = confidence interval.
doi:10.1371/journal.pone.0098405.t002
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partnered, as well as those with lower education, and a reversed
effect among all others. Among women, all effects were weak,
inconsistent and non-significant.
Discussion
Principal findings
Our aim was to elaborate the debated causal connection
between the rapid increase in antidepressant sales and the co-
occurring decline in suicide rates by applying a region and year
fixed-effects model which controls for all time invariant charac-
teristics of regions and all year-specific characteristics that may
influence suicide risk irrespective of regional antidepressant sales.
All in all, our results provide little support for the claim that
increase in overall sales or in the prevalence of non-tricyclic
antidepressant users would have caused the fall in suicide rates in
Finland in 1995–2007. However, our results suggest a beneficial
effect of increased antidepressant treatment among men—one
percentage point increase in the regional proportion of antide-
pressant users with minimally adequate treatment (i.e. 90 DDDs or
more annually) decreased the risk for non-alcohol-related male
suicide by 1%. This implies that, given the observed increase in
antidepressant sales, around half (63% with a 95% confidence
interval 11%–105%) of the observed decline in non-alcohol-
related male suicide rate could be explained by increased
proportion of antidepressant users receiving minimally adequate
treatment. The beneficial effect was observed among men with
higher education, higher income, and the employed, and among
those not owning their home and not living with a partner, whereas
among other social groups there was no effect. Alcohol-related
suicide and female suicide were unrelated to regional antidepres-
sant sales.
Potential explanations
Improved detection and adequacy of pharmacotherapy of
major depression has been reported for Finland during 1989–
2001, possibly due to an extensive suicide prevention program
implemented nationally in 1992–1996 [29]. Our results suggest
that the increasing proportion of antidepressant users receiving
minimally adequate treatment had a beneficial effect, whereas
mere per-capita sales and the prevalence of antidepressant users
were unrelated to suicide risk. Short-term and non-psychiatric use
of antidepressants has been found common in Finland and in
other countries [30,31]. If much of the rapidly expanding sales are
accounted for by such short-term and non-psychiatric use then the
effect on suicides is likely to be small. The increasing antidepres-
sant sales may have, however, prevented suicides via increased
adequacy of treatment, likely reflecting enhanced compliance.
We found no effect of antidepressant sales on female suicide,
although the prevalence of women using antidepressants has
almost tripled and the per-capita sales have more than quadrupled
during our study period. Female suicides are uncommon and
confidence intervals thus wide, so firm conclusions are difficult to
draw. However, mere lack of statistical power is unlikely to explain
our null finding since also the effect sizes among women were
much smaller or even reversed compared to those among men. A
Norwegian study from 1980–2004 found a beneficial effect of
regional antidepressant sales on suicide rates only during low sales
levels, and no effect during high sales [2]. This could also be true
for Finnish women. The start of the decline in suicide rates in the
early 1990s could have been caused by an increase in the then low
levels of antidepressant sales whereas during the time of our study
(1995–2007) further increase in antidepressant sales was no longer
reducing female suicides.
Among men, the beneficial effect of antidepressant sales was
only observed in some social groups, possibly reflecting differential
likelihood of receiving and complying with treatment. Men with
higher education, higher income, and employment may have
benefited more of the increase in antidepressant prescribing if they
have become more likely to be adequately treated when depressed.
One reason behind this could relate to better detection of
depression in higher social groups, although in Finland, detection
of psychiatric disorders among patients presenting in primary care
seems to be more likely among people with low education and
social status, partly because of case severity [32]. People from
higher social groups may also be more active in seeking treatment
and adhere to medication [33], possibly due to more economic
resources and better access to occupational health services. The
Table 3. Age-adjusted relative risk (RR) for non-alcohol-related suicide per unit change in the proportion of antidepressant users
who receive doses reflecting minimally adequate treatment by social factors among men (N= 463,807).
% of person-years RR 95% CI1 p2
Education, years 9+ 64.1 0.984 0.968–1.000 0.550
9 or less 35.9 0.991 0.975–1.007
Employed Yes 57.5 0.985 0.971–1.000 0.629
No 42.5 0.991 0.973–1.009
Individual income tertile 2nd or 3rd 77.1 0.985 0.971–1.000 0.565
Lowest 22.9 0.992 0.974–1.010
Home owner Yes 69.0 0.993 0.973–1.014 0.478
No 31.0 0.984 0.971–0.998
Living with a partner Yes 64.4 0.997 0.978–1.015 0.213
No 35.6 0.982 0.968–0.996
All 100 0.987 0.976–0.998
Region fixed effects yes
Year fixed effects yes
1CI = confidence interval.
2p-value for significance of effect modification by social factor.
doi:10.1371/journal.pone.0098405.t003
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seemingly contrasting result of a beneficial effect among those not
living in owned housing and those living without a partner may
reflect the fact that these groups also include all individuals living
in institutional settings. The institutionalized group may have
benefitted from increased antidepressant prescribing since due to
their institutional residence their mental health problems are likely
to be better detected and managed. However, since our data lack
any information on antidepressants administered in institutional
settings, this question is beyond the scope of our study. Men not
living in owned housing and men living without a partner are
high-risk groups for suicide and thus a beneficial effect observed in
these groups may also reflect a success in targeting treatment.
The reasons behind alcohol-related suicide risk being unaffected
by antidepressant sales require further investigation. Alcohol-
related suicides may differ clinically from non-alcohol-related
suicides. A Canadian psychological autopsy study found com-
pleters of alcohol-related suicides to be more impulsive and more
aggressive, to have lower education and to have more psychiatric
comorbidities than completers of non-alcohol-related suicides [34].
In Finland suicide attempters with alcohol-use disorders are less
likely to receive and comply with appropriate aftercare [35,36].
Correspondingly, in our data, only 10% of alcohol-related suicides
were preceded by minimally adequate antidepressant treatment
during the year of suicide, whereas for non-alcohol-related suicides
the proportion was over 20%. Further studies are needed to assess
whether this difference is due to differences in receipt of
antidepressant treatment, compliance with it, or both. The
alcohol-related suicide rate among Finnish men has stagnated in
the 2000s at around 10 per 100,000 person years, which is very
high compared with a 26-country-average overall suicide rate of 9.6
[16]. Although even in Finland, the bulk of suicides is non-alcohol-
related and has reacted to the increase in antidepressant
prescribing, the over 30% of male suicides that are alcohol-related
have not, and call for more rigorous prevention strategies.
Strengths and limitations
We used individual-level register data with nearly one million
individuals and negligible loss to follow-up. The accuracy and
reliability of the Finnish cause-of-death registration has been
ranked among the best in international comparisons [37].
Particularly, as medico-legal autopsies are carried out in over
90% of accidental and violent deaths in people under 65 [38],
alcohol intoxication as a contributory cause of suicide can be
reliably assessed in our data.
Although we use individual-level data, our explanatory variable
is measured at the regional level, not permitting us to assess the
effect of individual-level antidepressant use on suicide risk. Our
conclusions thus remain at the aggregate level: the causal
connection between falling suicide rates and increasing antide-
pressant sales seems to be limited to non-alcohol-related male
suicide.
We used region and time fixed-effects models to control for
regional differences and time trends that may influence suicide risk
irrespective of antidepressant sales. Previous aggregate-level
studies reporting a significantly beneficial effect of antidepressant
sales on suicide rates mostly use less stringent controls for time
[1,11,13,14,17], with the exceptions of one Norwegian [2] and one
cross-national study [16]. Controlling for time is essential for
inferring causality between two co-occurring trends because it
removes the confounding effects of all other co-occurring trends in
observed or unobserved factors, and thus effects are only inferred
from the variation between regions in the changes in antidepres-
sant sales.
It should be noted, though, that adding the year fixed effects
could be an over-adjustment if the year-to-year differences in
suicide rates common to all regions were in fact brought about by
the increase in overall antidepressant sales. In other words, if
regional variation in trends is small then controlling for everything
that is common across regions could mask beneficial effects of the
sales increase. Crude regional correlations between antidepressant
sales and suicide rates, however, implied that antidepressant sales
could explain a maximum of 40% of non-alcohol-related male
suicide rate, but less than 10% of alcohol-related male suicide rate
and 0–10% of female suicide rate. We thus believe that if there has
been a causal effect of increased antidepressant sales on suicide
rates it has mainly occurred for non-alcohol-related male suicides.
One limitation to our study is that regional-level antidepressant
data was only available from 1995 onwards and thus excludes the
period from the end of the 1980s when non-tricyclic antidepres-
sants were first introduced and the decline in suicide rates began in
Finland [3]. In particular since previous studies have shown
stronger effects during times of lower antidepressant sales [2,17],
our results are likely to underestimate any effect that the
introduction and early expansion of non-tricyclic antidepressant
before 1995 may have had on the declining suicide rates.
However, the decline in suicide rates has continued throughout
our study period and thus we should be able to observe effects of
increasing antidepressant sales.
Our results were mostly robust to different model specifications
and different measurement of antidepressant sales. However, the
significant reduction in non-alcohol-related male suicide with
increased proportion of antidepressant users receiving minimally
adequate treatment was not replicated when controlling for time
as a national linear trend or as regional linear trends, when
assessing suicide risk with one-year lag with respect to antidepres-
sant sales, or when minimally adequate treatment was defined as a
minimum of 180 defined daily doses instead of 90. We thus remain
cautious with the interpretation of a beneficial effect of rising
antidepressant sales on suicide risk among men.
Conclusions
We used individual-level register-data to study the association
between regional antidepressant sales and the risk for non-alcohol-
related and alcohol-related suicide in Finland in 1995–2007.
Increased proportion of antidepressant users who received doses
reflecting minimally adequate treatment may have prevented non-
alcohol-related suicides among men.
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